IFN-alpha Gene Therapy
1 drugs1
Approved Drugs
1
Companies
0
Indications
0
Therapeutic Areas
Top IFN-alpha Drugs
IFN-alpha Drug Modality Landscape
Modalities
Gene therapy
1
100%
Routes of Administration
💧 Other
1
100%
💡
Only one approved drug targets IFN-alpha, using gene therapy modality.
Biologics only
IFN-alpha Clinical Trials 7 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on IFN-alpha. Source: ClinicalTrials.gov. How we count
7
Total Trials
5
Active
1
Completed
50%
Completion Rate
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 1 | 0 | 0 | 1 | - |
| Phase 2 | 1 | 0 | 0 | 1 | - |
| Phase 3 | 4 | 1 | 0 | 3 | 100% |
| Phase 4 | 1 | 0 | 1 | 0 | 0% |
Top Sponsors
Ferring Pharmaceuticals 5 50%
Memorial Sloan Kettering Can... 1
University of Washington 1
By Modality
Gene therapy 7 50%
Top Conditions
Intermediate Risk Non-M... 1
Non-Muscle Invasive Bla... 1
Low-grade Upper Tract U... 1
Non-muscle Invasive Bla... 1
Muscle Invasive Bladder... 1
Stage II Bladder Cancer... 1
Stage IIIA Bladder Canc... 1
Bladder Cancer 1 0%
Ta/T1 1 0%
CIS 1 0%
Top Drugs
Source: ClinicalTrials.gov · Completion rate = completed ÷ (completed + terminated + withdrawn)
IFN-alpha Drug Approval Timeline (2022 - 2022)
Modalities: Gene therapy | First of modality
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 3 (1 company)
- • Completion rates by condition
Unlock Full Intelligence
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on IFN-alpha. A trial counts if an approved drug acting on IFN-alpha is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.